• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Gen9

edit

Gen9 is building on advances in synthetic biology to power a scalable fabrication capability that will significantly increase the world’s capacity to produce DNA content. The privately held company’s next-generation gene synthesis technology allows for the high-throughput, automated production of DNA constructs at lower cost and higher accuracy than previous methods on the market. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels.

Recent Milestones

edit

• 
  Gen9 received $21M in Private Equity funding. (4/24/13)
  Posted 4/24/13 at 6:39pm via finsmes.com
• 
  Gen9 received $395k in Debt funding. (5/22/12)
  Posted 5/22/12 at 4:18pm via masshightech.com
• 
  Gen9 received $1.5M in Venture Round funding. (9/9/11)
  Posted 9/9/11 at 5:17pm via masshightech.com
• 
  Gen9 — bumped up a previously disclosed financing, taking in $1.96 million of a planned $2.5 million debt offering (4/28/11)
  Posted 4/29/11 at 6:18am via masshightech.com
• 
  Gen9 received $1.7M in Venture Round funding. (2/11/11)
  Posted 2/13/11 at 11:06pm via masshightech.com
• 
  Gen9 added Joseph Jacobson as Co-Founder, Executive Chairman and CTO.
  Posted 7/11/12 at 6:16pm
• 
  Gen9 added Kevin Munnelly as President and CEO.
  Posted 7/11/12 at 6:16pm
• 
  Gen9 added Martin Goldberg as COO.
  Posted 7/11/12 at 6:16pm

Videos

Screenshots

edit

Sources

1. Gen9 raises $1.7M after founder’s death (masshightech.com) [edit]
2. Stealthy Gen9 nabs $1.5M in new funding (masshightech.com) [edit]
3. Gen9 receives $395K in debt financing (masshightech.com) [edit]
4. Gen9 Closes $21M Strategic Investment with Agilent Technologies (finsmes.com) [edit]
Synthetic bio startup Gen9 pulls in almost $2M financing (masshightech.com) [edit]